Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Deals

Genentech and Orionis Enter Second Collaboration on Small-Molecule Oncology Drugs

Fineline Cube May 22, 2025

Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY), this week entered...

Company Drug

Kexing Biopharm’s GB18 Receives FDA Approval for Tumor Cachexia Clinical Trial

Fineline Cube May 22, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced receiving clinical trial approval from the US...

Company Drug

Accropeutics’ AC-201 Shows Positive Phase II Results in Psoriasis Treatment

Fineline Cube May 22, 2025

Suzhou-based Accropeutics Bioscience announced positive results from a Phase II study for its AC-201 in...

Company Drug

Simcere’s FGFR2b-Targeting ADC SIM0686 Enters Phase I Clinical Study

Fineline Cube May 22, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced the initiation of a Phase I clinical study...

Company Drug

Triastek’s T22 Gastric Retention Capsules Gain NMPA IND Clearance

Fineline Cube May 22, 2025

Nanjing-based Triastek Inc., a pioneer in 3D-printed pharmaceutical formulations, has obtained Investigational New Drug (IND)...

Company Drug

Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke

Fineline Cube May 22, 2025

Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...

Company

Well Lead Medical to Set Up Subsidiary and Manufacturing Base in Indonesia

Fineline Cube May 22, 2025

Guangzhou-based medical catheter specialist Well Lead Medical Co., Ltd (SHA: 603309) plans to establish a...

Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer

Fineline Cube May 22, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that another indication approval filing for its...

Company Deals

Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&D

Fineline Cube May 22, 2025

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted...

Policy / Regulatory

HHS Implements Trump’s Order for Most-Favored-Nation Drug Pricing

Fineline Cube May 22, 2025

The U.S. Department of Health and Human Services (HHS) announced that it is taking immediate...

Company Drug

Nuance Pharma’s Ohtuvayre Meets Primary Endpoints in COPD Study

Fineline Cube May 22, 2025

China-based Nuance Pharma announced positive topline results from the ENHANCE-CHINA study (NCT05743075) for its nebulized...

Company Drug

AccurEdit Therapeutics’ ART001 Receives FDA RMAT Designation for ATTR

Fineline Cube May 22, 2025

China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Regenerative Medicine Advanced...

Company Deals

AstraZeneca Completes Acquisition of EsoBiotec for Up to USD 1 Billion

Fineline Cube May 22, 2025

UK-based major AstraZeneca (AZ; NASDAQ: AZN) announced the completion of its acquisition of EsoBiotec SA,...

Company Deals

Pulnovo Medical Raises Tens of Millions in New Financing Round

Fineline Cube May 21, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for hypertension and heart failure, announced...

Company Deals Medical Device

PHASE Scientific Completes Series A Financing to Advance Urine-Based Diagnostics

Fineline Cube May 21, 2025

Hong Kong-based urine-based diagnostics specialist PHASE Scientific International Limited announced the completion of a Series...

Policy / Regulatory

China’s CDE Announces 94th Batch of Reference Preparations for Generic Evaluation

Fineline Cube May 21, 2025

China’s Center for Drug Evaluation (CDE) has selected the 94th batch of reference preparations for...

Company Deals

Merck KGaA Partners with IMEC to Develop Advanced Microphysiological Systems Platform

Fineline Cube May 21, 2025

German major Merck KGaA (ETR: MRK) this week announced a partnership with Belgium-based Interuniversity Microelectronics Centre...

Company Deals Drug

Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors

Fineline Cube May 21, 2025

China-based Antengene Corporation Limited (HKG: 6996) has entered into a collaboration with US major Merck,...

Hospital Policy / Regulatory

China’s County Hospitals Show Improved Medical Service Capability in 2024

Fineline Cube May 21, 2025

The National Health Commission (NHC) released a notice reporting the status of the county hospital...

Company Drug

3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC

Fineline Cube May 21, 2025

China-based 3SBio Inc. (HKG: 1530) announced this week the registration of the first Phase III...

Posts pagination

1 … 149 150 151 … 657

Recent updates

  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
  • Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
  • China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.